Comparison of Target Pocket Similarity and Progress into Research on Inhibitors of Picornavirus 3C Proteases

被引:1
|
作者
Wan, Li [1 ]
Wang, Xiaobo [2 ]
Wang, Tangle [1 ]
Yuan, Xiaolan [1 ]
Liu, Wei [1 ]
Huang, Yan [1 ]
Deng, Changyong [1 ]
Cao, Shuang [1 ]
机构
[1] Wuhan Inst Technol, Minist Educ, Sch Chem Engn & Pharm, Key Lab Green Chem Engn Proc, Wuhan 430205, Peoples R China
[2] Hubei Univ Sci & Technol, Xianning Med Coll, Sch Pharm, Xianning 437100, Peoples R China
关键词
3C protease; similarity of target pockets; 3C protease inhibitors; STRUCTURE-BASED DESIGN; ENTEROVIRUS; 71; BIOLOGICAL EVALUATION; ANTIVIRAL ACTIVITY; IRREVERSIBLE INHIBITORS; SUBSTITUTED FLAVANOIDS; ISATIN DERIVATIVES; 3C-LIKE PROTEASES; STRUCTURAL BASIS; MAIN PROTEASE;
D O I
10.1002/cbdv.202201100
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The 3C protease (3C Pro) plays a significant role in the life cycle of picornaviruses from replication to translation, making it an attractive target for structure-based design of drugs against picornaviruses. The structurally related 3C-like protease (3CL Pro) is an important protein involved in the replication of coronaviruses. With the emergence of COVID-19 and consequent intensive research into 3CL Pro, development of 3CL Pro inhibitors has emerged as a popular topic. This article compares the similarities of the target pockets of various 3C and 3CL Pros from numerous pathogenic viruses. This article also reports several types of 3C Pro inhibitors that are currently undergoing extensive studies and introduces various structural modifications of 3C Pro inhibitors to provide a reference for the development of new and more effective inhibitors of 3C Pro and 3CL Pro.
引用
收藏
页数:24
相关论文
共 50 条
  • [21] Dual inhibition of human rhinovirus 2A and 3C proteases by homophthalimides
    Wang, QM
    Johnson, RB
    Jungheim, LN
    Cohen, JD
    Villarreal, EC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) : 916 - 920
  • [22] Differential temperature dependence of tobacco etch virus and rhinovirus 3C proteases
    Raran-Kurussi, Sreejith
    Toezser, Jozsef
    Cherry, Scott
    Tropea, Joseph E.
    Waugh, David S.
    ANALYTICAL BIOCHEMISTRY, 2013, 436 (02) : 142 - 144
  • [23] PIF-Pocket as a Target for C. albicans Pkh Selective Inhibitors
    Pastor-Flores, Daniel
    Schulze, Joerg O.
    Bahi, Anna
    Giacometti, Romina
    Ferrer-Dalmau, Jofre
    Passeron, Susana
    Engel, Matthias
    Suess, Evelyn
    Casamayor, Antonio
    Biondi, Ricardo M.
    ACS CHEMICAL BIOLOGY, 2013, 8 (10) : 2283 - 2292
  • [24] Research note: CCD photometry of blazars 3C 345, 3C 446 and 4C 56.27
    Argote, M
    Benitez, E
    Dultzin-Hacyan, D
    REVISTA MEXICANA DE ASTRONOMIA Y ASTROFISICA, 1998, 34 (02) : 83 - 86
  • [25] Research progress of CXCR3 inhibitors
    Yuan, Zhuo
    ANTI-CANCER DRUGS, 2024, 35 (01) : 36 - 45
  • [26] Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers
    Hui, Daniel H. F.
    Tam, Kevin J.
    Jiao, Ivy Z. F.
    Ong, Christopher J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (03)
  • [27] Homophthalimides are inhibitors of human rhinovirus 3C protease.
    Jungheim, LN
    Cohen, JD
    Wang, QM
    Johnson, RB
    Villarreal, EC
    Wakulchik, M
    Loncharich, RJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 274 - MEDI
  • [28] Non-covalent inhibitors of rhinovirus 3C protease
    Baxter, Andrew
    Chambers, Mark
    Edfeldt, Fredrik
    Edman, Karl
    Freeman, Adrian
    Johansson, Cristian
    King, Sarah
    Morley, Andy
    Petersen, Jens
    Rawlins, Phil
    Spadola, Loredana
    Thong, Bob
    Van de Poel, Herve
    Williams, Nicola
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (02) : 777 - 780
  • [29] Azapeptide inhibitors for human rhinovirus 3C proteinase.
    Nimkar, SK
    Venkatraman, S
    Kong, JS
    Aube, J
    Hanzlik, RP
    Wang, QM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 210 - MEDI
  • [30] Human rhinovirus 3C protease inhibitors: recent developments
    Wang, QM
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (09) : 1151 - 1156